Alzheimer Disease & Dementia

Bristol Myers Squibb's BMS-986446 receives FDA Fast Track Designation, aiming to transform early Alzheimer disease treatment by targeting tau pathology.

Late-life depression poses unique challenges, impacting cognitive function and requiring tailored treatment strategies for older adults.

INmune Bio reveals phase 2 trial results for XPro1595, a novel treatment targeting neuroinflammation in early Alzheimer disease.

Discover how blood-based biomarker testing revolutionizes Alzheimer diagnosis, offering a less invasive, efficient alternative to traditional methods.

Explore the challenges and strategies of deprescribing in geriatric psychiatry to enhance patient safety and reduce polypharmacy risks.

Apathy significantly affects cognitive impairment patients, yet remains underrecognized. Discover effective assessment and treatment strategies for improved outcomes.

Timing hormone replacement therapy post menopause significantly influences Alzheimer disease risk, with early treatment offering protective benefits against cognitive decline.

Discover how blarcamesine, a novel therapy for Alzheimer disease, shows promise in preventing cognitive decline and enhancing patient quality of life.

Susan Noonan, MD, discusses emerging research on the potential role of lithium deficiency in Alzheimer disease.

The FDA has approved the Leqembi subcutaneous autoinjector for at-home Alzheimer disease treatment.

Leqembi for the treatment of Alzheimer disease has been launched in Austria on August 25, 2025, and will be launched in Germany on September 1, 2025—the first launches in the EU.

New research highlights lithium's crucial role in brain health, revealing its potential to combat Alzheimer disease and enhance mental wellness.

Anavex Life Sciences reveals significant cognitive and functional improvements in early Alzheimer disease patients using blarcamesine, highlighting its potential as a long-term treatment.

Acumen Pharmaceuticals reveals a breakthrough blood assay that enhances Alzheimer’s trial efficiency and highlights sabirnetug's selectivity for toxic amyloid beta oligomers.

Cognition Therapeutics reveals promising phase 2 results for zervimesine in treating dementia with Lewy bodies and Alzheimer disease at AAIC 2025.

Roche unveils promising Alzheimer disease treatments and diagnostic tools, including trontinemab and the Elecsys pTau217 blood test, at the AAIC conference.

Gerald Maguire, MD, shares insights on agitation in Alzheimer disease at the Southern California Psychiatry Conference.

GLP-1 receptor agonists emerge as potential game-changers in psychiatric treatment, targeting mental disorders and improving cognitive function.

Explore effective strategies for dementia risk reduction and understand the importance of early cognitive assessments in aging adults.

Check out the pipeline updates from April!

In this CME article, explore the complexities of Parkinson disease, focusing on neuropsychiatric symptoms, their prevalence, and effective treatment strategies for improved patient care.

Does trontinemab represent the next generation of anti-amyloid monoclonal antibodies thanks to Brainshuttle technology? New research looks encouraging.

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

Check out the pipeline updates from January!